Rigel Pharmaceuticals | RIGL - Ebitda


Rigel Pharmaceuticals reported $-4.17M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
Agenus USD -10.11M 19.02M Mar/2025
Amgen USD 5.14B 775M Dec/2025
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD 57.17M 7.03M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Celldex Therapeutics USD -83.58M 2.76M Mar/2026
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Intrexon USD -24.7M 2.92M Jun/2024
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD 66.78M 83.54M Dec/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Veracyte USD 42.8M 488K Mar/2026